Antitumor effect of Programmed Death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse

Clinical Cancer Research

Volumn 23, Issue 1, 2017, Pages 149-158

  Ashizawa, Tadashi ^a   Iizuka, Akira ^a   Nonomura, Chizu ^a   Kondou, Ryota ^a   Maeda, Chie ^a   Miyata, Haruo ^a   Sugino, Takashi ^a   Mitsuya, Koichi ^a   Hayashi, Nakamasa ^a   Nakasu, Yoko ^a   Maruyama, Kouji ^a   Yamaguchi, Ken ^a   Katano, Ikumi ^b   Ito, Mamoru ^b   Akiyama, Yasuto ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CELL MARKER; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7 RECEPTOR; KI 67 ANTIGEN; LAG3 PROTEIN; NIVOLUMAB; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYTOKINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG CYTOTOXICITY; GENE EXPRESSION REGULATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; KNOCKOUT MOUSE; LYMPHOCYTIC INFILTRATION; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NATURAL KILLER CELL; NESTIN GENE; NOG MHC DOUBLE KNOCKOUT MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SPLEEN CELL; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ENGRAFTMENT; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; NEOPLASM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SURVIVAL ANALYSIS; TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CYTOKINES; DISEASE MODELS, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85010069213     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0122     Document Type: Article

References (40)

1. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-56.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2005;363:711-23.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
4. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
5. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
6. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolomab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
7. Larkin J, Chiarion-Sileni V, Gonzaliz R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
8. Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 32:5s, 2014 (suppl; abstr 8023).
9. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in nonhuman primates. Cancer Immunol Res 2014;2:846-56.
10. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-57.
11. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-82.
12. + cells using the NOD/SCID/gammacnull mice model. Blood 2003;102:873-80.
13. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloin cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hematopoietic stem cells. J Immunol 2005;174:6477-89.
14. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffarentti JC, Lanzavecchia A, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304:104-7.
15. Inoue M, Senju S, Hirata S, Irie A, Baba H, Nishimura Y. An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2gamma(null) (NOG) mice. Immunol Lett 2009;126:67-72.
16. Ito R, Shiina M, Saito Y, Tokuda Y, Kametani Y, Habu S. Antigen-specific antibody production of human B cells in NOG mice reconstituted with the human immune system. Curr Top Microbiol Immunol 2008;324:95-107.
17. Tonomura N, Habiro K, Shimizu A, Sykes M, Yang YG. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood 2008;111:4293-6.
18. Wege AK, Schmidt M, Ueberham E, Ponnath M, Ortmann O, Brockhoff G, et al. Co-transplantation of human hematopietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies. MAbs 2014;6:968-77.
19. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009;58:1195-206.
20. Sanmamed MF, Rodriguez I, Schalper KA, Onate C, Azpilikueta A, Rodriguez-Ruiz ME, et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice. Cancer Res 2015;75:3466-78.
21. Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 2009;87:1654-8.
22. Alcantar-Orozco EM, Gornall H, Baldan V, Hawkins RE, Gilham DE. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods 2013;24:310-20.
23. Yaguchi T, Kobayashi A, Katano I, Ka Y, Ito M, Kawakami Y. MHC class I/II deficient NOG mice are useful for analysis of human T/B cell responses for human tumor immunology research. J Immunother Cancer 2013;1:P39
24. Inoue K, Saegusa N, Omiya M, Ashizawa T, Miyata H, Komiyama M, et al. Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model. Cancer Sci 2015;106:143-50.
25. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarker for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19:1009-20.
26. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19:462-8.
27. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligand, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
28. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013;73:6800-912.
29. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603.
30. Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, et al. Interferon-g-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunol 2015;4:e1008824.
31. Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286-94.
32. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic change in vivo. J immunol 2015;194:950-9.
33. Song S, Yuan P, Wu H, Chen J, Fu J, Li P, et al. Dendritic cells with an increased PD-L1 by TGF-β induce T-cell energy for the cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol 2014;20:117-23.
34. Fu BH, Fu ZZ, Meng W, Gu T, Sun XD, Zhang Z. Platelet VEGF and serum TGF-b1 levels predict chemotherapy response in non-small cell lung cancer patients. Tumor Biol 2015;36:6477-83.
35. Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, et al. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy. Ann Surg Oncol 2014;21:2361-8.
36. Li S, Li Y, Qu X, Liu X, Liang J. Detection and significance of Treg FoxP3(+) and Th17 cells in peripheral blood of nonsmall cell lung cancer patients. Arch Med Sci 2014;10:232-9.
37. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, et al. Mesenchymal Forkhead1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007;104:10069-74.
38. Su HT, Weng CC, Hsiao PJ, Chen LH, Kuo TL, Chen YW, et al. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer. Mol Cancer Res 2013;11:768-79.
39. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res 2014;74:1045-55.
40. Pham CD, Flores C, Yang C, Pinheiro EM, Yearley JH, Sayour EJ, et al. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clin Cancer Res 2015;22:582-95.